effect
rang
metallopeptidas
inhibitor
activ
porcin
kidney
cell
surfac
zinc
aminopeptidas
aminopeptidas
apa
ec
aminopeptidas
n
apn
ec
aminopeptidas
w
apw
ec
directli
compar
amastatin
probestin
effect
three
aminopeptidas
eonentr
inhibitor
requir
caus
inhibit
iso
low
micromolar
rang
except
probestin
apn
display
nm
actinonin
fail
inhibit
significantli
either
apa
apw
thu
consid
rel
select
inhibitor
pm
apn
contrast
bestatin
rel
poor
inhibitor
apn
pm
fail
inhibit
apa
potent
toward
apw
pm
thu
observ
chemotherapeut
action
bestatin
may
due
inhibit
cellsurfac
apw
number
metallopeptidas
inhibitor
includ
inhibitor
ec
membran
dipeptidas
ec
phosphol
inhibitor
anotensin
convert
enzym
ec
fail
inhibit
significantli
apa
apn
apw
howev
apw
inhibit
lzo
valu
micromolar
rang
sulphydryl
convert
enzym
inhibitor
rentiapril
pm
zofenoprilat
pm
ys
pm
neither
apa
apn
affect
sulphydryl
compound
inhibit
apw
may
account
side
effect
note
clinic
use
sulphydryl
convert
enzym
inhibitor
avail
compound
total
setect
apw
mammalian
ceil
surfac
zinc
aminopeptidas
may
aid
identifi
endogen
substrat
thu
physiolog
pathophysiolog
role
apw
mammalian
cell
surfac
peptidas
involv
metabol
rang
af
biolog
activ
peptid
includingpeptid
hormon
neuropeptid
dietari
peptid
prove
therapeut
target
varieti
diseas
state
includ
heart
diseas
inflamm
metastasi
sever
cell
surfac
peptidas
recent
identifi
cluster
differenti
cd
antigen
exampl
ec
shown
ident
common
acut
lymphocyt
leukaemia
antigen
calla
cdlo
aminopeptidas
n
apn
ec
dipeptidyl
peptidas
iv
ec
aminopeptidas
apa
ec
murin
plymphocyt
differenti
antigen
role
peptidas
metastasi
unclear
although
termin
gener
peptid
signal
affect
prolifer
transform
normal
cell
possibl
addit
apn
identifi
recent
receptor
pig
human
coronavirus
tgev
respect
zinc
aminopeptidas
constitut
rel
larg
subdivis
mammalian
cell
surfac
correspond
author
tel
fax
abbrevi
apa
aminopeptidas
apn
aminopeptidas
n
apw
aminopeptidas
w
app
aminopeptidas
p
cd
cluster
differenti
antigen
concentr
inhibitor
requir
tocaus
inhibit
peptidas
famili
date
four
distinct
enzym
character
apn
apa
aminopeptidas
p
app
ec
aminopeptidas
w
apw
ec
app
somewhat
differ
three
anchor
plasma
membran
moieti
lo
strict
requir
pro
penultim
posit
suscept
substrat
apn
best
character
class
display
broad
substrat
specif
identifi
major
activ
releas
ntermin
tyr
enkephalin
enzym
may
also
play
role
metabol
neurokinin
apa
hydrolys
acid
residu
nterminu
suscept
substrat
may
involv
uivo
convers
angiotensin
angiotensin
iii
apw
preferenti
hydrolys
short
peptid
exhibit
maxim
rate
toward
diptid
pi
residu
aromat
far
apw
implic
metabol
biolog
activ
peptid
due
part
lack
select
inhibitor
specif
latter
three
aminopeptidas
overlap
certain
extent
often
lead
difficulti
identifi
unequivoc
enzym
respons
metabol
particular
peptid
although
sever
inhibitorsof
aminopeptidas
avail
effect
one
enzym
observ
recent
certain
compound
design
supposedli
select
inhibitor
angiotensin
convert
enzym
ec
also
inhibit
app
valu
micromolar
rang
present
studi
extend
work
directli
compar
effect
rang
convert
enzym
inhibitor
activ
apa
n
w
attempt
identifi
compound
could
use
discrimin
activ
thu
use
tool
delin
role
particular
peptidas
metabol
biolog
activ
peptid
addit
reassess
inhibitori
profil
number
compound
character
inhibitor
zinc
aminopeptidas
apn
apw
purifi
pig
kidney
cortex
describ
previous
effect
activ
apa
n
w
specif
metallopeptidas
inhibitor
final
concentr
mm
examin
aminopeptidas
assay
appropri
substrat
describ
materi
method
result
mean
sem
three
independ
determin
inhibitor
arnintjass
maxim
l
f
except
orphan
caus
inhibit
apw
inhibit
three
aminopeptidas
amastatin
bestatin
probestin
examin
detail
fig
amastatin
equipot
three
aminopeptidas
howev
probestin
potent
inhibitor
apn
either
apa
apw
respect
contrast
bestatin
iifold
potent
inhibitor
apw
tso
um
apn
ym
effect
activ
apa
n
w
specif
inhibitor
angiotensin
convert
enzym
final
concentr
mm
also
examin
tabl
apa
significantli
inhibit
maxim
inhibitor
test
ndolaprilat
pentopritat
ramiprifat
spirapritat
caus
partial
inhibit
maxim
apn
none
carboxylalkyl
phosphoryl
inhibitor
caus
inhibit
apw
howev
sulphydryl
compound
captoprii
rentiapril
ys
zofenoprilat
caus
signific
inhibit
apw
effect
sulphydryl
compound
activ
apw
examin
detail
fig
result
indic
rentiapril
pm
potent
inhibit
apw
zofenoprilat
pm
ys
pm
captopril
fm
increasingli
less
potent
present
studi
directli
compar
c
ys
captopril
tabl
result
somewhat
surpris
bestatin
long
consid
potent
inhibitor
apn
use
extens
inhibit
activ
metabol
studi
origin
note
howev
bestatin
inhibit
monkey
canin
kidney
cell
surfac
leucin
aminopeptidas
activ
probabl
apn
valu
rang
bestatin
shown
display
immunomodul
properti
act
antitumour
agent
chemotherapeut
action
believ
due
part
inhibit
cell
surfac
apn
howev
light
present
result
action
may
eitheralso
due
inhibit
cell
surfac
apw
probestin
isol
recent
streptomyc
azureu
shown
inhibit
apn
present
studi
show
probestin
also
inhibit
apa
apw
valu
micromolar
rang
see
tabl
thu
probestin
appear
rel
broad
act
aminopeptidas
inhibitor
although
somewhat
potent
apn
amastatin
origin
identifi
inhibitor
apa
sinc
shown
inhibit
also
apn
apw
studi
directli
compar
inhibitori
potenc
amastatin
apa
n
w
obtain
result
agreement
earlier
report
indic
amastatin
essenti
equipot
three
enzym
see
tabl
actinonin
origin
identifi
inhibitor
apn
lack
activ
toward
apa
also
shown
inhibit
apw
result
confirm
present
studi
see
tabl
thu
within
cell
surfac
aminopeptidas
famili
actinonin
consid
select
inhibitor
apn
due
key
role
play
angiotensin
convert
enzym
reninangiotensin
system
numer
inhibitor
zinc
peptidyl
dipeptidas
synthes
use
success
treatment
hypertens
congest
heart
failur
compound
divid
three
class
depend
group
coordin
activ
site
zinc
atom
sulphydryl
ii
carboxylalkyl
iii
phosphoryl
recent
observ
app
sensit
inhibit
convert
enzym
inhibitor
present
studi
extend
observ
assess
effect
inhibitor
angiotensin
convert
enzym
apa
n
w
none
compound
examin
caus
signific
inhibit
apa
apn
howev
sulphydryl
compound
rentiapril
zofenoprilat
ys
inhibit
apw
valu
micromolar
rang
pm
sulphydryl
compound
analogu
captopril
ys
structur
ident
captopril
apart
sulphur
atom
posit
prolyl
ring
zofenoprilat
differ
captopril
possess
aromat
ring
attach
posit
prolyl
ring
sulphur
bridg
rentiapril
differ
ys
hydroxyl
aromat
ring
attach
posit
prolyl
ring
increas
potenc
toward
apw
rentiapril
zofenoprilat
may
due
larg
aromat
moieti
mimick
aromat
pi
residu
substrat
order
potenc
sulphydryl
compound
essenti
revers
seen
app
order
ys
pm
captopril
um
zofenoprilat
usa
rentiapril
caus
inhibit
concentr
mm
slight
inhibit
apw
observ
thiorphan
tabl
probabl
also
due
zinc
coordin
sulphydryl
group
compound
even
though
sulphydryl
convert
enzym
inhibitor
loofold
less
potent
inhibit
apw
angiotensin
convert
enzym
vitro
valu
micromolar
rang
may
signific
caus
inhibit
apw
vivo
exampl
teprotid
first
effect
convert
enzym
inhibitor
vivo
display
rso
toward
enzym
pm
addit
inhibitor
membran
dipeptidas
ec
cilastatin
coadminist
actam
antibiot
imipenem
prevent
metabol
dipeptidas
kidney
display
valu
fm
vitro
clinic
use
numer
side
effect
note
captopril
includ
cough
skin
rash
tast
disturb
caus
advers
effect
remain
unclear
ahhough
similar
side
effect
note
penicillamin
lead
specul
sulphydryl
group
may
respons
result
present
studi
suggest
effect
may
due
addit
inhibit
apw
sulphydryl
convert
enzym
inhibitor
conclus
shown
amastatin
probestin
broad
inhibitori
profil
act
three
cell
surfac
zinc
aminopeptidas
n
w
also
confirm
actinonin
rel
select
inhibitor
apn
bestatin
rel
poor
inhibitor
peptidas
much
potent
toward
apw
rais
question
whether
chemotherapeut
properti
bestatin
may
involv
inhibit
apw
observ
sulphydryl
convert
enzym
inhibitor
rentiapril
zofenoprilat
rel
potent
total
specif
apw
cell
surfac
zinc
aminopeptidas
enabl
role
enzym
metabol
bioactiv
peptid
normal
diseas
situat
assess
may
explain
side
effect
note
clinic
use
compound
howev
select
inhibitor
apa
identifi
